Avonex Kit
Product Images NDC 59627-222

Product Visual Gallery

This gallery contains 66 technical images submitted to the FDA as part of the official labeling for Avonex (NDC 59627-222). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biogen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Avo08 0020 01

A line graph titled 'Time to Onset of Sustained Disability Progression in Patients with MS in Study 1' shows the percentage of patients progressing over weeks (0 to 104). Two lines compare AVONEX vs. placebo, indicating about 22% progression in AVONEX group and 35% in placebo by study end. A statistical significance P value of 0.02 is noted.*

FDA Label Image

Avo08 0020 02

A bar chart titled 'Confirmed Change in EDSS from Study Entry to End of Study 1' comparing the percentage of patients with different levels of confirmed change from baseline EDSS between Avonex (N=150) and Placebo (N=136). The x-axis shows categories of change from <-1.0 to >=2.0, with annotations indicating better and worse outcomes, and the y-axis shows the percentage of patients. The chart highlights statistical significance with a p-value of 0.006.*

FDA Label Image

Avo08 0020 03

A line graph titled 'Time to onset of a Second Exacerbation in Study 2' compares AVONEX and placebo groups over 36 months. The y-axis shows the percentage of patients with a second exacerbation, and the x-axis marks time in months. The graph includes a table with the number of subjects at risk each interval for both groups and statistical values (P = 0.002, Rate Ratio = 0.56).*

FDA Label Image

Avo08 0020 04

Illustration showing components of the Avonex Pen injection device, 30 mcg. It labels the blue activation button, tamper-evident cap, injector shield with grooved area, body of the pen, needle cover with attached foil, and the Avonex Pen cover, highlighting parts relevant to its intramuscular injection use.*

FDA Label Image

Avo08 0020 05

An instructional image showing a hand holding an Avonex Pen injection device. The focus is on the cap removal step before use, highlighted with a dotted circle and the word "Before" below the device. This illustrates preparation for administering the Avonex Pen, an intramuscular injection of Interferon Beta-1a 30 mcg/0.5 mL by Biogen Inc.*

FDA Label Image

Avo08 0020 06

An instructional illustration showing a person's hands preparing an Avonex Pen (Interferon Beta-1a injection) by peeling back a purple tab on the pen's protective cap, likely as a step before administration.*

FDA Label Image

Avo08 0020 07

An instructional illustration highlighting the glass syringe tip of an Avonex Pen injection device for intramuscular use. The image shows a close-up of the pen's tip with a label pointing to the 'glass syringe tip,' emphasizing the component after removal or preparation.*

FDA Label Image

Avo08 0020 08

An instructional illustration showing a hand holding an Avonex Pen for injection. The image depicts the step of preparing the pen by twisting or removing a cap or cover before administering the intramuscular injection of Interferon Beta-1a.*

FDA Label Image

Avo08 0020 09

An instructional illustration showing hands preparing an Avonex Pen (Interferon Beta-1a) injection. The image demonstrates holding the pen and positioning a protective cap over the injection site before administration. Arrows indicate the direction of cap placement or removal steps in the injection preparation process.*

FDA Label Image

Avo08 0020 10

An instructional illustration showing hands assembling or preparing an Avonex Pen injection device. The image visually demonstrates the process of removing or securing a purple component on the pen injector, used for intramuscular administration of Interferon Beta-1a, 30 mcg/0.5 mL, by Biogen Inc.*

FDA Label Image

Avo08 0020 11

An instructional illustration showing the Avonex Pen injection device preparing for administration. The image focuses on the connection point labeled 'After (attached needle),' highlighting the final step of attaching the needle to the pen before use.*

FDA Label Image

Avo08 0020 12

An instructional illustration showing a person preparing an Avonex Pen for use. The image depicts two hands: one hand holding the pen device and the other hand removing its cap. The background is plain white, focusing on the device and the demonstration of its handling.*

FDA Label Image

Avo08 0020 13

An instructional illustration showing how to hold and use the Avonex Pen injector. The image depicts hands grasping the pen with an arrow indicating the extension action, demonstrating the step "After (extended)" in the injection process for Avonex Pen, 30 mcg/0.5 mL intramuscular solution by Biogen Inc.*

FDA Label Image

Avo08 0020 14

Illustration highlighting the safety lock feature visible on the Avonex Pen, an injectable interferon beta-1a solution for intramuscular use by Biogen Inc.*

FDA Label Image

Avo08 0020 15

Image shows the oval medicine display window of an Avonex Pen, a prefilled autoinjector for Interferon Beta-1a injection solution. The window is designed to indicate medicine presence inside the pen. The labeler is Biogen Inc.*

FDA Label Image

Avo08 0020 16

An instructional illustration showing the correct intramuscular injection site on a human thigh. The highlighted red area indicates the recommended location for administering an injection, depicting the anatomical region to target.*

FDA Label Image

Avo08 0020 17

An instructional illustration showing the administration of an intramuscular injection into the thigh. A hand holding a syringe is positioned near the outer thigh of a seated person, demonstrating the injection technique.*

FDA Label Image

Avo08 0020 18

Illustration showing a hand holding an injection pen positioned near the outer thigh of a person. A purple arrow indicates the injection site area on the thigh, outlined with a dashed red box. The image demonstrates proper intramuscular injection technique or site for a medication like Avonex Pen.*

FDA Label Image

Avo08 0020 19

Illustration showing a circular display window on the Avonex Pen injection device, highlighting a specific part of the pen intended for user interaction or indication.*

FDA Label Image

Avo08 0020 20

An instructional illustration depicting the proper site for intramuscular injection on the upper thigh. It shows a hand holding a syringe with the injection area highlighted by a red dashed box and a purple arrow pointing to the site just above the knee on the outer thigh.*

FDA Label Image

Avo08 0020 21

An instructional illustration showing the safety lock mechanism on the Avonex Pen injection device. The left side shows the safety lock visible, and the right side shows the safety lock released, demonstrating how to set the pen for injection.*

FDA Label Image

Avo08 0020 22

An instructional illustration showing a hand holding an Avonex Pen injection device near a bent arm with the outer upper arm exposed. The image depicts the proper injection site and technique for intramuscular administration of the Avonex Pen (Interferon Beta-1a 30 mcg/0.5 mL). An arrow indicates the direction for needle insertion into the arm.*

FDA Label Image

Avo08 0020 23

A blue stopwatch graphic displaying the text '10 sec' in white, indicating a time interval of ten seconds. The stopwatch design includes a top button and minute markers around the circular edge.*

FDA Label Image

Avo08 0020 24

An instructional illustration demonstrating the use of an Avonex Pen. The left side shows a person holding their arm, possibly preparing for injection, while the right side shows a hand holding the Avonex Pen with an arrow indicating movement or injection direction. The image depicts steps in administering an intramuscular injection using the Avonex Pen for Interferon Beta-1a.*

FDA Label Image

Avo08 0020 25

The image shows an Avonex Pen, a prefilled injection device containing Interferon Beta-1a 30 mcg/0.5 mL for intramuscular use. The pen is white with a blue grip and features a circular display window near the top end, highlighting part of the device's interface. The labeler is Biogen Inc.*

FDA Label Image

Avo08 0020 26

Illustration showing a hand holding an Avonex Pen injection device vertically with an arrow pointing downward, indicating the direction for use or administration. The image demonstrates part of the injection process for the Avonex Pen containing Interferon Beta-1a 30 mcg/0.5 mL injection solution.*

FDA Label Image

Avo08 0020 27

Avonex Pen 30 micrograms/0.5 mL injection solution in an intramuscular prefilled pen device, labeled with the brand name and manufacturer Biogen Inc. The pen features a white cylindrical design with text and a large orange button near the top and blue text at the bottom.*

FDA Label Image

Avo08 0020 28

An illustration showing parts of an Avonex Pen injection syringe labeled as Syringe, Protective rubber cover, and Cap. The syringe is displayed vertically with clear markings and components identified for user reference.*

FDA Label Image

Avo08 0020 29

Illustration showing a hand holding an Avonex Pen pre-filled syringe for intramuscular injection. The image demonstrates the proper grip and handling technique of the Avonex Pen, which contains 30 micrograms per 0.5 mL of Interferon Beta-1a, manufactured by Biogen Inc.*

FDA Label Image

Avo08 0020 30

An instructional illustration showing hands preparing an Avonex Pen for injection. One hand holds the pen while the other pulls off a purple-colored cap from the needle end, demonstrating the preparation step for administering an intramuscular injection of Interferon Beta-1a 30 mcg/.5 mL solution.*

FDA Label Image

Avo08 0020 31

An instructional illustration showing the attachment of a pen device (likely the Avonex Pen) to a vial or cartridge. The image depicts the pen being aligned and inserted at a 90-degree angle into the vial cap, indicated by a purple curved arrow.*

FDA Label Image

Avo08 0020 32

An instructional illustration shows the steps to prepare an Avonex Pen injection. It includes a needle cover and a glass syringe tip, with hands demonstrating how to remove the needle cover by pulling it off from the glass syringe tip. The diagram visually guides the user through the preparation process for the Avonex Pen injection, solution, 30 mcg/0.5 mL by Biogen Inc.*

FDA Label Image

Avo08 0020 33

An instructional illustration showing a person holding and preparing an Avonex Pen prefilled syringe with Interferon Beta-1a injection solution, 30 mcg/0.5 mL. The image focuses on the hand positioning for removing the pen cap prior to intramuscular injection.*

FDA Label Image

Avo08 0020 34

An anatomical illustration showing front and side views of a human leg with a highlighted rectangular area on the upper thigh, indicating the recommended site for intramuscular injection administration.*

FDA Label Image

Avo08 0020 35

Illustration depicting an arm with a highlighted area on the upper arm, indicating the recommended intramuscular injection site for the Avonex Pen (Interferon Beta-1a) 30 mcg/0.5 mL injection solution.*

FDA Label Image

Avo08 0020 36

An instructional illustration showing hands assembling an injection device with a syringe and needle. The image depicts a step in preparing the Avonex Pen (Interferon Beta-1a) intramuscular injection, 30 ug/.5mL, by Biogen Inc., demonstrating attaching the needle to the syringe with a directional arrow.*

FDA Label Image

Avo08 0020 37

An instructional illustration showing a hand holding an Avonex Pen above a person's upper arm, with an arrow indicating to insert the injection at a 90-degree angle into the muscle for intramuscular administration.*

FDA Label Image

Avo08 0020 38

An instructional illustration showing a hand pressing the plunger of a syringe to inject Avonex Pen (Interferon Beta-1a) intramuscularly. The image focuses on the injection process with an arrow pointing to the plunger being pushed into the injection site on the arm.*

FDA Label Image

Avo08 0020 39

An instructional illustration showing a hand holding a syringe pen at a 90-degree angle above an injection site on an arm, with an arrow indicating an upward motion for administering the intramuscular injection. This relates to the Avonex Pen injection process.*

FDA Label Image

Avo08 0020 40

An instructional diagram labeling parts of the Avonex Pen injection device, showing the syringe, protective rubber cover, and cap components of the intramuscular injection solution.*

FDA Label Image

Avo08 0020 41

Illustration showing a hand holding an Avonex Pen autoinjector device. The device is used for intramuscular injection of Avonex (Interferon Beta-1a) 30 mcg/0.5 mL solution. The image highlights the pen's size and grip for administering the medication.*

FDA Label Image

Avo08 0020 42

Instructional illustration showing two hands holding an Avonex Pen, demonstrating the technique to pull the cap straight off the pen by gripping the cap with one hand and holding the pen body with the other, with a red arrow indicating the upward pulling motion.*

FDA Label Image

Avo08 0020 43

An instructional illustration showing a step in the use of the Avonex Pen, displaying the pen with its protective cap being rotated or removed, indicated by a red curved arrow. The focus is on preparing the pen for injection.*

FDA Label Image

Avo08 0020 44

Instructional illustration showing a hand holding an Avonex Pen injection device, demonstrating preparation steps with the other hand pulling or pushing a part of the pen, indicated by a red downward arrow. The image depicts proper handling before administration of the intramuscular injection solution.*

FDA Label Image

Avo08 0020 45

An instructional illustration showing a person using a syringe to draw solution from a vial or vial-like container. The hands demonstrate the technique of inserting the needle into the vial and pulling back the plunger to withdraw the medication.*

FDA Label Image

Avo08 0020 46

The image shows a set of Avonex Pen dose divider inserts for the Interferon Beta-1a injection solution, labeled for intramuscular use. The set includes three color-coded plastic inserts indicating 1/4 dose (white), 1/2 dose (yellow), and 3/4 dose (purple), each marked with dose volume and corresponding week.*

FDA Label Image

Avo08 0020 47

An illustration showing the upper portion of the Avonex Pen injection device. The image highlights the collar area located near the top, just below the plunger mechanism. This diagram is related to the Avonex Pen for intramuscular injection of Interferon Beta-1a 30 mcg/0.5 mL, labeled by Biogen Inc.*

FDA Label Image

Avo08 0020 48

Avonex Pen, containing Interferon Beta-1a 30 mcg/0.5 mL injection solution for intramuscular use. The image shows the prefilled syringe injector device in a neutral background, with visible markings on the syringe barrel and the integrated needle cover. The product is labeled by Biogen Inc.*

FDA Label Image

Avo08 0020 49

Avonex Pen 30 mcg/0.5 mL injection solution, intramuscular, showing a single-dose prefilled syringe with a yellow protective shield. The syringe is branded with the Avonex mark and designed for patient self-administration. Labeler is Biogen Inc.*

FDA Label Image

Avo08 0020 50

Avonex Pen containing Interferon Beta-1a 30 mcg/0.5 mL solution for intramuscular injection. The image shows a prefilled autoinjector pen in purple color with dose markings and a transparent section displaying the liquid medication. The labeler is Biogen Inc.*

FDA Label Image

Avo08 0020 51

Avonex Pen 30 mcg/0.5 mL injection, solution for intramuscular use. The image shows the prefilled injection pen device designed for single-dose use, labeled with the product name and strength. Manufactured by Biogen Inc.*

FDA Label Image

Avo08 0020 52

Illustration of the Avonex Pen, a single-use autoinjector device for administering Interferon Beta-1a injection solution intramuscularly. The device includes a prefilled syringe with a needle attached, designed to deliver a 30 microgram dose in 0.5 mL. The pen is shown in a transparent view highlighting internal components, including the syringe barrel, plunger, and needle.*

FDA Label Image

Avo08 0020 53

An illustration showing a transparent syringe-like device with a plunger and needle, indicated by two red arrows pointing to the top compartment of the device. The device appears to be related to a prefilled pen injection system, likely for administering medication intramuscularly.*

FDA Label Image

Avo08 0020 54

An instructional illustration showing hands preparing the Avonex Pen injection. One hand holds the barrel of the prefilled syringe labeled with a 0.5 mL dose, and the other hand is indicated by a red arrow to turn or adjust a component near the needle, demonstrating part of the injection setup process for intramuscular administration.*

FDA Label Image

Avo08 0020 55

An illustration showing two views of a human leg with red shaded areas on the upper outer thigh, indicating recommended intramuscular injection sites for Avonex Pen (Interferon Beta-1a) 30 mcg/0.5 mL solution.*

FDA Label Image

Avo08 0020 56

An illustration showing the recommended injection site for Avonex Pen (Interferon Beta-1a) 30 mcg/0.5 mL solution. The site highlighted is the upper outer arm, indicating where an intramuscular injection should be administered.*

FDA Label Image

Avo08 0020 57

An instructional diagram showing the connection of a needle to the Avonex Pen injection device. It depicts hands holding the pen and the needle, with a red arrow indicating the direction to attach the needle to the pen for administration.*

FDA Label Image

Avo08 0020 58

An instructional illustration showing the use of an Avonex Pen injection device. The image depicts a hand holding the Avonex Pen to administer an intramuscular injection into the lower arm of another person, with a red arrow indicating downward pressure for injection.*

FDA Label Image

Avo08 0020 59

An illustration showing the hand positioning and technique for administering an Avonex Pen injection intramuscularly. The image depicts fingers holding the pen device preparing for injection, demonstrating proper grip and use.*

FDA Label Image

Avo08 0020 60

An instructional illustration showing a hand holding an Avonex Pen syringe above a person's skin, demonstrating the injection process with an upward arrow indicating the syringe movement. The syringe contains a clear solution with visible markings.*

FDA Label Image

Avo08 0020 61

A dose titration schedule table for Avonex Pen (Interferon Beta-1a) showing weekly dose progression from week 1 to week 4. It lists doses as 1/4, 1/2, 3/4, and full dose, matched with titration device colors white, yellow, purple, and none respectively, alongside columns for week and date/time.*

FDA Label Image

Avo08 0020 62

Label for Avonex Pen (interferon beta-1a) 30 mcg/0.5 mL single-dose prefilled autoinjector for intramuscular injection. The package indicates once-a-week dosing and includes an administration dose pack. Manufactured by Biogen Inc., with storage instructions and caution regarding natural rubber latex.*

FDA Label Image

Avo08 0020 63

Avonex Pen 30 mcg/0.5 mL Injection packaging label for a single-dose prefilled syringe containing interferon beta-1a for intramuscular injection. The label shows Biogen Inc. as the manufacturer and states the product is for once a week use. It includes storage instructions, caution about natural rubber latex, absence of preservatives, and no U.S. standard of potency. The package contains one prefilled syringe and one needle.*

FDA Label Image

Avo08 0020 64

Packaging label for Avonex Pen, a 30 mcg/0.5 mL single-dose prefilled autoinjector injection for intramuscular use by Biogen Inc. The label indicates administration once a week and includes 4 Avonex Pen Administration Dose Packs with accessories. Storage instructions, manufacturer details, and NDC 59627-333-04 are visible.*

FDA Label Image

Avo08 0020 65

Packaging label for Avonex Pen (interferon beta-1a) Injection, 30 mcg/0.5 mL single-dose prefilled syringe for intramuscular injection, once a week. The label indicates contents include 4 Avonex administration dose packs and provides storage and caution information. Labeler is Biogen Inc.*

FDA Label Image

Avo08 0020 66

Label for Avonex Pen (Interferon Beta-1a) 30 mcg/0.5 mL single-dose prefilled syringe for intramuscular injection. The label includes storage instructions, caution about natural rubber latex, and manufacturer Biogen Inc., Cambridge, MA. The label also features a barcode and NDC number 59627-002-07.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.